http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005053904-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15a41c6c77e3a54013384d0465bc093e
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C01B31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409
filingDate 2004-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76a40511db3e2ef3fb299fc50d9d60d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec14dcc00bf4e7f3b37bc872a912ce31
publicationDate 2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2005053904-A
titleOfInvention Fullerenes and anticancer therapeutic agents
abstract 【Task】 In boron neutron capture therapy, which is a cancer treatment, an anti-cancer therapeutic agent with a compound of 10 B added to a cancer affinity group is sent to cancer cells, irradiated with thermal neutrons, and alpha rays generated by nuclear reactions. Cancer cells were selectively destroyed. However, there is a problem that Li produced after the reaction is harmful to the human body. [Solution] An anticancer therapeutic agent in which a cancer affinity group was added to fullerenes encapsulating 10 B or 6 Li was used as a therapeutic agent for neutron capture therapy. Since 10 B or 6 Li is confined in fullerenes that are highly safe for the human body, the safety of neutron capture therapy can be improved. [Selection] Figure 1
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015156385-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2015156385-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012134337-A1
priorityDate 2003-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002255518-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002241307-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002212197-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H09235235-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70006845
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415872004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559581
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450974914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID485223053
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID429368612
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6337058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148246181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559586
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12465958
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66868
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID194637
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID297
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410538120
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578835
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462311

Total number of triples: 41.